Individualised obesity therapy - tailoring interventions to a person's phenotypes
Phenotype-tailored lifestyle interventions may result in significant weight loss according to the results from a pilot study of 165...
top of page
Browse by category
Search
EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...
NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...
Bariatric surgery reduces mortality in patients with obesity and sleep apnoea
Bariatric surgery was associated with a 42% lower risk of major adverse cardiovascular events (MACE), including heart failure, heart...
Despite lowering BMI threshold for eligibility, access to surgery remains low
Despite patient eligibility for bariatric surgery expanding over the last decade and its safety and effectiveness even further...
Metabolic surgery results in fewer heart attacks, strokes and death among patients with diabetes
Patients with diabetes and a history of metabolic surgery had significantly fewer heart attacks, strokes, hospitalisations and death,...
T2DM remains in remission six years after RYGB regardless of weight loss
More than half of patients (51%) with type 2 diabetes and a history of metabolic surgery experienced remission of their diabetes even if...
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks
Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...
GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron
Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...
Browse by tag
bottom of page